Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.
Aim. Тo determine the serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention. Materials and methods We examined 23 type 1 diabetic patient with microangyopathy and arterial hypertention, 10 type 1 diabetic patient with microangyopathy without hypertention...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2016-09-01
|
Series: | Сахарный диабет |
Subjects: | |
Online Access: | https://dia-endojournals.ru/dia/article/viewFile/7674/6039 |
id |
doaj-f02c5b841db24e72815ed8a6e4d772b2 |
---|---|
record_format |
Article |
spelling |
doaj-f02c5b841db24e72815ed8a6e4d772b22021-06-02T21:12:27ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782016-09-0119430931410.14341/DM76747503Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.Liliya A. Mogylnytska0Boris N. Mankovsky1Khmelnitsky regional hospitalNational Medical Academy for Postgraduate EducationAim. Тo determine the serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention. Materials and methods We examined 23 type 1 diabetic patient with microangyopathy and arterial hypertention, 10 type 1 diabetic patient with microangyopathy without hypertention and 28 control subjects. Serum levels of EMAP-II were determined by immunoenzyme assay. The data were presented as means±SD. Results. We found an increased serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention compared to control group (5,23±1,66 ng/ml and 1,25±0,76 ng/ml respectively, р0,01), and in type 1 diabetic patients with microangyopathy and arterial hypertension compared to group without hypertension (5,23±1,66 ng/ml and 3,63±1,9 ng/ml respectively, р0,01). Also, the level of EMAP-II correlated with key markers of carbohydrate and lipid metabolism, inverse correlated with endothelium-dependent dilatation (p0,05). Conclusion. The revealed change of EMAP-II could reflect an endothelial dysfunction in patients with type 1 diabetes with microangyopathy and arterial hypertension. Arterial hypertension, hyperglycemia, dyslipidemia appears to be significant factor to contributing elevation of EMAP-II. Keywords: Endothelial monocyte activating polypeptide II, endothelial dysfunction, type 1 diabetes, arterial hypertension.https://dia-endojournals.ru/dia/article/viewFile/7674/6039endothelial monocyte-activating polypeptide iiendothelial dysfunctiontype 1 diabetesarterial hypertension |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Liliya A. Mogylnytska Boris N. Mankovsky |
spellingShingle |
Liliya A. Mogylnytska Boris N. Mankovsky Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention. Сахарный диабет endothelial monocyte-activating polypeptide ii endothelial dysfunction type 1 diabetes arterial hypertension |
author_facet |
Liliya A. Mogylnytska Boris N. Mankovsky |
author_sort |
Liliya A. Mogylnytska |
title |
Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention. |
title_short |
Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention. |
title_full |
Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention. |
title_fullStr |
Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention. |
title_full_unstemmed |
Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention. |
title_sort |
serum levels of endothelial monocyte activating polypeptide-ii in type 1 diabetes patients with microangyopathy and arterial hypertention. |
publisher |
Endocrinology Research Centre |
series |
Сахарный диабет |
issn |
2072-0351 2072-0378 |
publishDate |
2016-09-01 |
description |
Aim. Тo determine the serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention.
Materials and methods We examined 23 type 1 diabetic patient with microangyopathy and arterial hypertention, 10 type 1 diabetic patient with microangyopathy without hypertention and 28 control subjects. Serum levels of EMAP-II were determined by immunoenzyme assay. The data were presented as means±SD.
Results. We found an increased serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention compared to control group (5,23±1,66 ng/ml and 1,25±0,76 ng/ml respectively, р0,01), and in type 1 diabetic patients with microangyopathy and arterial hypertension compared to group without hypertension (5,23±1,66 ng/ml and 3,63±1,9 ng/ml respectively, р0,01). Also, the level of EMAP-II correlated with key markers of carbohydrate and lipid metabolism, inverse correlated with endothelium-dependent dilatation (p0,05).
Conclusion. The revealed change of EMAP-II could reflect an endothelial dysfunction in patients with type 1 diabetes with microangyopathy and arterial hypertension. Arterial hypertension, hyperglycemia, dyslipidemia appears to be significant factor to contributing elevation of EMAP-II.
Keywords: Endothelial monocyte activating polypeptide II, endothelial dysfunction, type 1 diabetes, arterial hypertension. |
topic |
endothelial monocyte-activating polypeptide ii endothelial dysfunction type 1 diabetes arterial hypertension |
url |
https://dia-endojournals.ru/dia/article/viewFile/7674/6039 |
work_keys_str_mv |
AT liliyaamogylnytska serumlevelsofendothelialmonocyteactivatingpolypeptideiiintype1diabetespatientswithmicroangyopathyandarterialhypertention AT borisnmankovsky serumlevelsofendothelialmonocyteactivatingpolypeptideiiintype1diabetespatientswithmicroangyopathyandarterialhypertention |
_version_ |
1721400758417489920 |